Biomarin rumors - The shuttering of research into exon-skipping therapies for DMD more than offset rumors that Sanofi SA (SNY 0.08%) could be considering a bid to buy the company, and as a result, BioMarin's shares ...

 
Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. Earlier, Merck acquired erstwhile Acceleron Pharma for …. Accuweather macomb mi

Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.Lizzo - Rumors feat. Cardi BListen/Download: https://lizzo.lnk.to/RumorsVisit Lizzo's website for tour dates, exclusive merch and more: http://www.lizzomusic...No. 3: Roche will buy BioMarin Pharmaceutical In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche (RHHBY 1.30%) was ...BioMarin's stock (NASDAQ: BMRN) closed Thursday at $88.93 per share, down from Monday when it opened at $93.50, and it again slipped 2.5% on Friday. Piper Sandler Analyst Chris Raymond suggests ...In March, the FDA said it needed more time to review a three-year analysis from BioMarin's ongoing Phase 3 GENEr8-1 study of Hemophilia A gene therapy, which BioMarin submitted earlier this year.BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.Dive Brief: BioMarin Pharmaceutical plans to lay off roughly 120 employees, or 4% of its global workforce, as part of a larger restructuring effort announced Thursday.; The California-based drugmaker, which built a business around medicines for exceedingly rare diseases, said the reorganization will reflect its transition into a global, large-scale biopharmaceutical company with a more diverse ...BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) has been identified as a likely acquisition target. There were rumors that Sanofi (ENXTPA:SAN) might pursue the company after it lost out to Pfizer (PFE) in acquiring Medivation (MDVN).Despite early rumors of a revamp with tier-one European stars, Evil Geniuses will enter the new season with a reworked North American roster, promoting the bulk of its academy squad.Questions about whether it would work for a lifetime or just a few years came amid rumors that Biomarin might set a price tag as high as $3 million per patient. ... Biomarin has estimated the ...Biomarin is a highly successful biotech company, specialising in curing rare diseases with gene therapy. I'll first explain it's drastic undervaluation before later explaining the upcoming catalyst and the ideal play. This is not some shitty penny stock or 50/50 bet. Biomarin has already developed 6 blockbuster drugs that generated revenues of ...BioMarin After quite the regulatory process, with Roctavian (valoctocogene roxaparvovec) BioMarin has a potential blockbuster. On June 29th, Roctavian became the first gene therapy approved in...The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. As companies chase growth that ...ACADIA (ACAD) Stock Price, News, Quote; History - Yahoo Finance. Find the latest ACADIA (ACAD) stock quote, history, news and other vital information to help you with your stock trading and investing.BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.1 Mei 2023 ... ... BioMarin Pharmaceutical, Blueprint Medicines, Emergent BioSolutions ... rumors of Pfizer's potential acquisition of Seagen surfaced. Company ...Sep 13, 2023, 2:04 AM. Will GTA 6 Be 750GB In Size And Cost $150? Separating Truth From Clickbait. In recent weeks, Take-Two Interactive Software Inc.'s (NASDAQ: TTWO) upcoming GTA 6 has been the ...BioMarin's shareholders reacted positively to the rumor. Shares were trading midday at $83.68, up $2.88 or 3.6% since market's open. But most people familiar with the matter say the rumors are ...Jun 25, 2020 · Rumor has it that the French pharmaceutical giant has its eyes on San Rafael, California-based Biomarin Pharmaceutical Inc. (NASDAQ:BMRN). Speculation heated up after Sanofi announced it was... Mar 6, 2023 · BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has a market capitalization of $18.877 billion. ClearBridge Sustainability Leaders Strategy made the following comment about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in its Q4 2022 investor letter: "Biotechnology stocks led our health care holdings: Gilead Sciences (GILD) shares rose sharply ... Rumors. Best Stocks & ETFs. Best Penny Stocks. ... The leading companies working in the AAV Vectors in Gene Therapy market include BioMarin Pharmaceutical, Gensight Biologics, PTC therapeutics ...Just published: Discover our new official Biotech Investments M&A target list for H2 2022. https://biotech-investments.com/top-biotech-merger-acquistion-takeover ...We use Google Analytics cookies to collect information in the aggregate to give us insight into how our website is being used. We anonymise IP addresses in Google Analytics, and the anonymised data are transmitted to and stored by Google on servers in the U.S. Google may also transfer this information to third parties where required by law, or where third …AnswerThePublic listens into autocomplete data from search engines like Google then quickly cranks out every useful phrase and question people are asking around biomarin on 02 May. It’s a goldmine of consumer insight you can use to create fresh, ultra-useful content, products and services. The kind your customers really want.About BioMarin. Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies ...Jun 17, 2016 · Shares of rare-disease drugmaker BioMarin climbed Friday morning on speculation that that the French pharma giant could be zeroing in on it as a backup plan. Jul 31, 2023 · Rumors. Best Stocks & ETFs. Best Penny Stocks. Best S&P 500 ETFs. ... BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% ... Feb 9, 2022. SAN RAFAEL, Calif., Feb. 9, 2022 / PRNewswire / -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has entered into a definitive agreement with an undisclosed purchaser to sell the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in November 2021 for a lump sum payment of $110,000,000.29 Jun 2023 ... The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical's gene therapy for severe hemophilia A, the company said, ...BioMarin will host a conference call and webcast to discuss fourth quarter and full year 2019 financial results and 2020 guidance today, Wednesday, February 26, 2020 at 4:30 p.m. ET. This event can be accessed on the investor section of the BioMarin website at www.biomarin.com. U.S./Canada Dial-in Number: 866.502.9859.Aug. 14. RE. CSL Limited Provides Revenue Guidance for the Fiscal Year 2024. Aug. 14. CI. CSL Limited Announces Final Dividend for 2023, to Be Paid on 4 October 2023. Aug. 14. CI. CSL Limited Reports Earnings Results for the Full Year Ended June 30, 2023.Discover historical prices for BMRN stock on Yahoo Finance. View daily, weekly or monthly format back to when BioMarin Pharmaceutical Inc. stock was issued. 20 Apr 2022 ... BioMarin (NASDAQ:BMRN): a rare disease gene therapy company with an attractive valuation; Crispr (NASDAQ:CRSP): powerful platform technology ...BioMarin Pharmaceutical an Biotechnology company,Founded March 1997,biomarin pharmaceutical stock,biomarin pharmaceutical address,biomarin ... biomarin pharmaceutical stock biomarin pharmaceutical address biomarin pipeline biomarin news biomarin products biomarin rumors biomarin achondroplasia …Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent BioMarin in recruitment activities. We have an established recruitment process which is required for all posted positions by BioMarin prior to issuing an offer of employment. This BioMarin process requires formal interviews conducted live with …Aug 19, 2020 · Questions about whether it would work for a lifetime or just a few years came amid rumors that Biomarin might set a price tag as high as $3 million per patient. ... Biomarin has estimated the ... A self-described aspiring farmer's attempt to show off her homegrown watermelon turned into a mishap that TikTok viewers were thrilled was caught on camera. The post Woman’s ‘homegrown watermelon’ reveal turns into a ‘rollercoaster of emotions’ appeared first on In The Know. 4d ago.Associate Director, Quantitative Science - UK (also open in the US) London, United Kingdom. Associate Director, Quantitative Science - US (Also opened in UK) San Rafael, California. Director, Quantitative Science (Post - Approval) San Rafael, California. Senior Manager, Data Management Science.You may also report side effects to BioMarin at 1-866-906-6100. Please see the ROCTAVIAN full Prescribing Information for additional Important Safety Information. About BioMarin. Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery.Apr 26, 2023 · (1) Enzyme-based products include ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ, and VIMIZIM. (2) GAAP Net income in the first quarter of 2022, included a $89.0 million net gain, net of taxes related to the sale of the Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the U.S. Food and Drug Administration (FDA) in connection with U.S. approval of VOXZOGO. The U.S. Federal Trade Commission said on Tuesday it has filed a lawsuit to stop Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics Plc in a rare move to block a large pharmaceutical deal.Hope. It's where BioMarin's story begins. It's what we work to deliver every day. And it’s what makes being here truly special. Good people doing work that does good. Powerful therapies empowering people’s lives. Rare opportunities sprung from treating rare diseases. These things shape the work experience and provide a powerful connection ...As of November 2015, rumors of an eminent divorce between Barack Obama and Michelle Obama are baseless. Rumors have been persistent since 2010, with the latest round attributed to gossip tabloid The National Enquirer.The U.S. Food and Drug Administration (FDA) has extended the review of BioMarin Pharmaceutical Inc's experimental gene therapy for adults with a severe bleeding disorder, the latest delay in the ...For years, rumors have circulated around the internet about the existence, and use, of paid protestors. In 2018, BuzzFeed News published an article titled “How Facebook Groups Are Being Exploited To Spread Misinformation, Plan Harassment, A...On March 3, 2023, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock closed at $101.20 per share. One-month return of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was -9.79%, and its shares gained 36. ...487 questions people are asking about biomarin. From 🇬🇧 United Kingdom in English 80 new popular searches discovered on 02 Jul Data updating in 5 days biomarin pharmaceutical biomarin stock biomarin share price biomarin london biomarin uk biomarin pipeline biomarin. Where is this data from?BioMarin US:BMRN is another mid-sized biotech stock that’s long been a buyout candidate. The California company focuses on rare diseases with so-called “orphan drugs.” These are treatments ...BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report CRISPR Therapeutics AG (CRSP): Free Stock Analysis ReportBioMarin US:BMRN is another mid-sized biotech stock that’s long been a buyout candidate. The California company focuses on rare diseases with so-called “orphan drugs.” These are treatments ...Apr 21, 2022 · BioMarin (NASDAQ: BMRN): ... (OTC: RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. BioMarin Pharmaceutical (NASDAQ: BMRN) rose 3.3% on "vague" speculation of potential takeover interest. BioMarin may be a takeover candidate for an …(Reuters) - BioMarin Pharmaceuticals, in a lawsuit filed in San Francisco federal court, has accused a former engineer who left the company for one of its main competitors in the gene-therapy...Given Bienaime's statement that BioMarin would not be interested in an acquisition even at a 25% to 30% premium, that would set a buyout price in the neighborhood of $90 per share based on the ...European Commission Approval Decision Expected Q4 2023. Opinion Based on Positive Results from Global Phase 2 and Ongoing Extension Study U.S. Food and Drug Administration PDUFA Target Action Date for Supplemental New Drug Application for VOXZOGO for Children Under 5 is Oct. 21, 2023. SAN RAFAEL, Calif., Sept. 15, 2023 …Rumor has it that the French pharmaceutical giant has its eyes on San Rafael, California-based Biomarin Pharmaceutical Inc. (NASDAQ:BMRN). Speculation …BioMarin Pharmaceutical Inc. is a biotechnology company that specializes in developing therapies for rare genetic diseases. The company was founded in 1997 and is headquartered in San Rafael, California, with operations in the United States, Europe, Latin America, and Asia. BioMarin’s mission is to improve the lives of patients with serious ... BioMarin Pharmaceutical Inc BMRN said that the FDA had requested additional information regarding the clinical hold on PHEARLESS Phase 1/2 study of BMN 307 issued in September 2021.. BMN 307 is an ...BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.Questions about whether it would work for a lifetime or just a few years came amid rumors that Biomarin might set a price tag as high as $3 million per patient. ... Biomarin has estimated the ...No. 3: Roche will buy BioMarin Pharmaceutical In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche (RHHBY 1.30%) was ...Oct 10, 2023 11:46am. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. And M&A activity still looks fairly lively in 2020 despite a ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2023 Earnings Call Transcript April 26, 2023 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.27, expectations were $0.18.About BioMarin. Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies ...iStock offer stock information, like fair price, target price and crucial economic indicator to help investor to find the best stockBioMarin's shareholders reacted positively to the rumor. Shares were trading midday at $83.68, up $2.88 or 3.6% since market's open. But most people familiar with the matter say the rumors are ...BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.BioMarin Pharmaceutical (NASDAQ:BMRN) +4.8% premarket on rumors that Glaxo (NYSE:GSK) is in advanced discussions toward a $5B buyout of BMRN.BioMarin Pharmaceutical plans to lay off roughly 120 employees, or 4% of its global workforce, as part of a larger restructuring effort announced Thursday. The California-based drugmaker, which built a business around medicines for exceedingly rare diseases, said the reorganization will reflect its transition into a global, large-scale ...Baird calls rumors of a GlaxoSmithKline (GSK +1.7%) takeout of Biomarin (BMRN +2.2%) "gossip" after an article in the Telegraph suggested the company was in " advanced"...Interested in #biotech stocks? Below you can find our official takeover target list for H2 2023. https://biotech-investments.com/top-biotech-merger-acquistion ...BioMarin has plenty of experience launching rare disease drugs, but the company's newest roll | BioMarin has plenty of experience launching rare disease drugs, but the company's …Aug 19, 2020 · SVB Leerink analyst Joseph Schwartz on Wednesday slashed his 12-month price target for BioMarin’s stock from $140 to $113 per share. He called the FDA ruling a “major negative surprise,” but ... BioMarin's stock (NASDAQ: BMRN) closed Thursday at $88.93 per share, down from Monday when it opened at $93.50, and it again slipped 2.5% on Friday. Piper Sandler Analyst Chris Raymond suggests ...The shuttering of research into exon-skipping therapies for DMD more than offset rumors that Sanofi SA (SNY 0.08%) could be considering a bid to buy the company, and as a result, BioMarin's shares ...BioMarin ($BMRN) has long been rumored to be a takeout candidate. Roche ($RHHBY), in particular, has before been highlighted as a potential suitor for it. BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date. July 12, 2023. BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET. BioMarin is a world leader in developing and ...Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. Earlier, Merck acquired erstwhile Acceleron Pharma for …BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.The shuttering of research into exon-skipping therapies for DMD more than offset rumors that Sanofi SA (SNY 0.08%) could be considering a bid to buy the company, and as a result, BioMarin's shares ...Jun 25, 2020 · Rumor has it that the French pharmaceutical giant has its eyes on San Rafael, California-based Biomarin Pharmaceutical Inc. (NASDAQ:BMRN). Speculation heated up after Sanofi announced it was... Dive Brief: BioMarin Pharmaceutical plans to lay off roughly 120 employees, or 4% of its global workforce, as part of a larger restructuring effort announced Thursday.; The California-based drugmaker, which built a business around medicines for exceedingly rare diseases, said the reorganization will reflect its transition into a global, large-scale biopharmaceutical company with a more diverse ...Mar 6, 2023 · BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has a market capitalization of $18.877 billion. ClearBridge Sustainability Leaders Strategy made the following comment about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in its Q4 2022 investor letter: "Biotechnology stocks led our health care holdings: Gilead Sciences (GILD) shares rose sharply ... Sep 22, 2023 11:22am. BioMarin ($BMRN) has long been rumored to be a takeout candidate. Roche ($RHHBY), in particular, has before been highlighted as a potential suitor for it. | BioMarin has long ...Just published: Discover our new official Biotech Investments M&A target list for H2 2022. https://biotech-investments.com/top-biotech-merger-acquistion-takeover ...Jun 29, 2023 · BioMarin ( NASDAQ: BMRN) is a $17bn market cap (at the time of writing) commercial stage pharmaceutical company that is often spoken about as an attractive target for a larger Pharma engaging in M ... Source: Shutterstock. BioMarin(NASDAQ: BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic ...21 Jun 2021 ... Michael O'Donnell, site leader, Shanbally, explains why BioMarin's unique culture gained such positive feedback in a recent staff survey.A blog post that, by its own admission, "might be codswallop," reported that the former is considering buying the latter. And those three facts combined to send the shares of BioMarin, far from a ...Rumor has it that the French pharmaceutical giant has its eyes on San Rafael, California-based Biomarin Pharmaceutical Inc. (NASDAQ:BMRN). Speculation heated up after Sanofi announced it was...BioMarin Pharmaceutical Inc. BMRN. Companies that have a product portfolio/pipeline of rare disease drugs are in great demand as it is a less competitive space and the expensive treatments can ...

Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. Earlier, Merck acquired erstwhile Acceleron Pharma for …. Rvu calculator cpt

biomarin rumors

Oct 10, 2023 11:46am. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. And M&A activity still looks fairly lively in 2020 despite a ...Rumor has it that the French pharmaceutical giant has its eyes on San Rafael, California-based Biomarin Pharmaceutical Inc. (NASDAQ:BMRN). Speculation heated up after Sanofi announced it was...Sep 13, 2023, 2:04 AM. Will GTA 6 Be 750GB In Size And Cost $150? Separating Truth From Clickbait. In recent weeks, Take-Two Interactive Software Inc.'s (NASDAQ: TTWO) upcoming GTA 6 has been the ... Jul 31, 2023 · Rumors. Best Stocks & ETFs. Best Penny Stocks. Best S&P 500 ETFs. ... BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% ... June 29 (Reuters) - The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical's (BMRN.O) gene therapy for severe hemophilia A, the company said, giving patients with the ...The average PE ratio therefore is 64% higher than Biomarin's current PE ratio meaning that BMRN is deeply undervalued compared to its peers. The fact that Biomarin's ROS is almost 3x as high as the peer group average further emphasises the company's quality. Simply Wallstreet has a price target of 155$ for BMRN based on a DCF analysis and ... BioMarin Pharmaceutical has delayed plans to resubmit an approval application to the Food and Drug Administration for its experimental hemophilia gene …29 Jun 2023 ... The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical's gene therapy for severe hemophilia A, the company said, ...BioMarin's (NASDAQ:BMRN) ... @Mktneutralhedger I think there is a chance of a takeover, but there are no rumors about this yet. Reply Like (1) I. Igor Ignatev. 29 Sep. 2021. Comments (1) Good points.Discover historical prices for BMRN stock on Yahoo Finance. View daily, weekly or monthly format back to when BioMarin Pharmaceutical Inc. stock was issued. Another day, another buyout rumor. Today it's BioMarin's turn in the takeover spotlight, after Dealreporter broke a story claiming that Roche is now scouting for $15 billion to buy the rare ...As far as I know, since I joined the company, from 17 years ago now as CEO, there were rumors that we would be acquired. A lot of companies that were rumored to acquire by BioMarin actually have ...Oct 10, 2023 · 22 Wall Street analysts have issued 1 year target prices for BioMarin Pharmaceutical's stock. Their BMRN share price forecasts range from $78.00 to $185.00. On average, they anticipate the company's stock price to reach $115.62 in the next year. This suggests a possible upside of 30.9% from the stock's current price. BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. As companies chase growth that ...BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.Novartis is getting a huge influx of cash from selling its 20-year stake in Roche, triggering speculation about where the Swiss pharma will spend the money.Oct 4, 2023 10:53am Sanofi is pushing full steam ahead with its hostile takeover try for Medivation. But rumor has it the California drugmaker may not be the only one on its target list. | Sanofi...CRISPR Therapeutics ( CRSP -0.77%), BioMarin Pharmaceutical ( BMRN -0.86%), and Sight Sciences ( SGHT 2.12%) all stand out as potential healthcare stocks that are excellent takeover targets this ...Aug. 14. RE. CSL Limited Provides Revenue Guidance for the Fiscal Year 2024. Aug. 14. CI. CSL Limited Announces Final Dividend for 2023, to Be Paid on 4 October 2023. Aug. 14. CI. CSL Limited Reports Earnings Results for the Full Year Ended June 30, 2023..

Popular Topics